Maximus, Inc. (NYSE:MMS) has been assigned a consensus rating of “Hold” from the ten research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and eight have issued a hold recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $61.00.
A number of research firms recently weighed in on MMS. KeyCorp reaffirmed a “sector weight” rating on shares of Maximus in a research report on Thursday, May 25th. ValuEngine cut shares of Maximus from a “buy” rating to a “hold” rating in a research report on Tuesday, May 16th. Canaccord Genuity cut shares of Maximus from a “buy” rating to a “hold” rating and set a $62.00 price target for the company. in a research report on Tuesday, July 4th. BidaskClub lowered shares of Maximus from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 6th. Finally, Zacks Investment Research upgraded shares of Maximus from a “sell” rating to a “hold” rating in a research note on Wednesday, July 26th.
In related news, insider Mark Andrekovich sold 8,939 shares of the company’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $64.01, for a total transaction of $572,185.39. Following the completion of the transaction, the insider now owns 24,583 shares of the company’s stock, valued at $1,573,557.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Richard A. Montoni sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $62.81, for a total transaction of $1,884,300.00. Following the transaction, the chief executive officer now directly owns 584,114 shares of the company’s stock, valued at approximately $36,688,200.34. The disclosure for this sale can be found here. In the last three months, insiders have sold 109,636 shares of company stock worth $6,874,122. 3.10% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in the company. Meritage Portfolio Management acquired a new stake in Maximus during the first quarter valued at about $5,668,000. Nationwide Fund Advisors increased its stake in Maximus by 16.9% in the first quarter. Nationwide Fund Advisors now owns 357,173 shares of the health services provider’s stock valued at $22,216,000 after buying an additional 51,639 shares in the last quarter. Navellier & Associates Inc increased its stake in Maximus by 10.9% in the first quarter. Navellier & Associates Inc now owns 8,737 shares of the health services provider’s stock valued at $543,000 after buying an additional 856 shares in the last quarter. West Coast Financial LLC acquired a new stake in Maximus during the first quarter valued at about $3,026,000. Finally, Alta Capital Management LLC increased its stake in Maximus by 2.9% in the first quarter. Alta Capital Management LLC now owns 640,174 shares of the health services provider’s stock valued at $39,818,000 after buying an additional 17,950 shares in the last quarter. Institutional investors own 97.89% of the company’s stock.
Shares of Maximus (NYSE MMS) traded down 1.10% during mid-day trading on Tuesday, hitting $60.23. The company’s stock had a trading volume of 251,166 shares. The stock’s 50 day moving average price is $61.60 and its 200 day moving average price is $60.73. The company has a market cap of $3.90 billion, a price-to-earnings ratio of 19.75 and a beta of 1.39. Maximus has a 52-week low of $43.69 and a 52-week high of $64.97.
Maximus (NYSE:MMS) last posted its quarterly earnings data on Thursday, August 3rd. The health services provider reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.76 by $0.03. The firm had revenue of $600.40 million during the quarter, compared to analysts’ expectations of $614.12 million. Maximus had a net margin of 8.43% and a return on equity of 25.08%. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter last year, the company posted $0.79 EPS. Equities analysts forecast that Maximus will post $3.12 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, August 31st. Stockholders of record on Tuesday, August 15th will be issued a $0.045 dividend. This represents a $0.18 annualized dividend and a dividend yield of 0.30%. The ex-dividend date of this dividend is Friday, August 11th. Maximus’s payout ratio is 5.73%.
TRADEMARK VIOLATION NOTICE: This article was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://sportsperspectives.com/2017/08/10/maximus-inc-nysemms-receives-61-00-average-price-target-from-brokerages-updated.html.
Maximus Company Profile
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.